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Background:Na/K-ATPase decrease has been reported in patients with heart failure and is related to cardiac dysfunction.
Results: Reducing Na/K-ATPase activates caspase 9 and induces cardiac dilation when treated with marinobufagenin.
Conclusion: Reduction of Na/K-ATPase potentiates marinobufagenin-induced cardiac myocyte apoptosis.
Significance: Decreased Na/K-ATPase content together with increased cardiotonic steroids levels is a novel mechanism that
may account for cardiac dysfunction.
Decreases in cardiac Na/K-ATPase have been documented in
patients with heart failure. Reduction of Na/K-ATPase 1 also
contributes to the deficiency in cardiac contractility in animal
models. Our previous studies demonstrate that reduction of cel-
lular Na/K-ATPase causes cell growth inhibition and cell death
in renal proximal tubule cells. To test whether reduction of
Na/K-ATPase in combination with increased cardiotonic ste-
roids causes cardiac myocyte death and cardiac dysfunction, we
examined heart function in Na/K-ATPase 1 heterozygote
knock-outmice (1/) in comparison to wild type (WT) litter-
mates after infusion of marinobufagenin (MBG). Adult cardiac
myocytes were also isolated from both WT and 1/mice for
in vitro experiments. The results demonstrated that MBG infu-
sion increased myocyte apoptosis and induced significant left
ventricle dilation in1/mice but not in theirWT littermates.
Mechanistically, it was found that inWTmyocytesMBGactivated
the Src/Akt/mTOR signaling pathway, which further increased
phosphorylation of ribosome S6 kinase (S6K) and BAD (Bcl-2-as-
sociated death promoter) and protected cells from apoptosis. In
1/ myocytes, the basal level of phospho-BAD is higher com-
paredwithWTmyocytes, butMBG failed to induce further activa-
tionof themTORpathway.ReductionofNa/K-ATPasealsocaused
the activation of caspase 9 but not caspase 8 in these cells. Using
cultures of neonatal cardiacmyocytes, we demonstrated that inhi-
bition of the mTOR pathway by rapamycin also enabled MBG to
activate caspase 9 and inducemyocyte apoptosis.
Reduction ofNa/K-ATPase has beendocumented in patients
and experimental animals with congestive heart failure (1, 2),
aging (3, 4), diabetes with hypertension (5–7), and neurological
disorders (8, 9). In heart tissue biopsies from patients with
dilated cardiomyopathy, the Na/K-ATPase amount is de-
creased by up to 40% (1). Reduction of cardiac Na/K-ATPase is
also related with decreased cardiac contractile function in
humans and in animals (1, 10, 11). Previous reports showed that
exposure of cells to low concentrations of cardiotonic steroids
(CTS)2 stimulates cell growth (12–14). Our recent work also
shows that binding of ouabain to Na/K-ATPase in pig renal
proximal tubule cells stimulates Src/Akt/mTOR signaling
pathways and results in a stimulation of cell growth. Interest-
ingly, the stimulatory effects of CTS on cell growth are abol-
ished when cellular Na/K-ATPase is reduced by siRNA (15).
In addition to the reduction of Na/K-ATPase, studies have
found that levels of endogenous CTS increase in patients and in
experimental animals with volume expanded hypertension and
chronic renal disease (16–18). It was also found that endoge-
nous ouabain-like compounds increased in patients with left
ventricular dysfunction due to dilated myocardium (19).
Because myocyte death may play an important role in develop-
ment ofmyocardium dilation and heart failure (20), the current
study tested whether reduction of Na/K-ATPase potentiates
CTS-induced myocyte apoptosis and cardiac dysfunction.
EXPERIMENTAL PROCEDURES
Animals—All animal experimentation described in this arti-
cle was conducted in accordance with theNational Institutes of
Health’s Guide for the Care and Use of Laboratory Animals
Committee. All procedures were approved by the Institutional
Animal Care and Use Committee at the University of Toledo.
The Na/K-ATPase heterozygous (1/) mice and their wild
type littermates were generated as described previously (11).* This work was supported, in whole or in part, by National Institutes of
Health, NHLBI Grants HL-105649, HL-109015, andHL-36573. This workwas
also supported by American Heart Association Grant 0980027N.
1 To whom correspondence should be addressed: Dept. of Medicine Cardio-
vascular Div., University of Toledo, 3000 Arlington Ave., MS 1008, Toledo,
OH 43614. Tel.: 419-383-3923; Fax: 419-383-3821; E-mail: Jiang.tian@
utoledo.edu.
2 The abbreviations used are: CTS, cardiotonic steroids; MBG, marinobufage-
nin; mTOR, the mammalian target of rapamycin; RIPA, radioimmune
precipitation assay; PI, propidium iodide; BAD, Bcl-2-associated death
promoter.
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Genomic DNA was obtained from tail biopsies and used for
PCR-based genotyping. Adult mice at 23 months were used
for the study. All mice were kept in a 12-h dark/light cycle and
fed standard chow ad libitum. Experimental mice were anes-
thetized and an osmotic mini-pump from Alzet (Cupertino,
CA) was placed under the skin to constantly infuseMBG at the
dose of 10 g/kg/day. Mice infused with solvent only (50%
dimethyl sulfoxide and 50% saline) were used as control. Dopp-
ler imaging study was performed at the end of the 4th week of
infusion as described before (21). Mice were sacrificed at the
end of 4th week after echocardiographic measurements. Blood
was collected, and the heartwas then removed. Thewhole heart
and isolated left ventricle were weighed. Afterward, half of the
left ventricle was snap frozen in liquid nitrogen, whereas the
other half was fixed in 4% formalin solution for histology anal-
ysis. Tissue homogenates for biochemistry analysis were
obtained by grinding tissues in liquid nitrogen and thenhomog-
enized in radioimmune precipitation assay buffer (50 mM Tris-
HCl, pH 7.4, 150mMNaCl, 0.25% deoxycholic acid, 1%Nonidet
P-40, 1 mM EDTA). RIPA buffer was supplemented with 1 mM
PMSF, 1 mM sodium orthovanadate, and 1% protease inhibitor
cocktails from Sigma before use.
Adult CardiacMyocyte Preparation fromMice—Ca2-toler-
ant adult mouse cardiac myocytes were prepared from isolated
hearts as described previously by O’Connell et al. (22) with
minor modifications. Briefly, mice were heparinized and anes-
thetized with Nembutal (100–140 mg/kg) via intraperitoneal
injection. The isolated heart was cannulated via the aorta and
perfused with calcium-free solution for 5 min followed by a
solution containing 1 mg/ml type II collagenase. The yield of
myocytes per heart was 1.0 million cells with 70–90% viable
rod-shaped cells. Cell attachment rate was 80%. Myocytes
were plated at the density of 25,000/ml on laminin (1.25
g/cm2)-coated Petri dishes in modified Eagle’s medium with
Hanks’ balanced salt solution supplemented with fetal bovine
serum (10%), 2,3-butanedione monoxime (10 mmol/liter) and
100 units/ml penicillin in a 2%CO2 incubator for 1 h. Cells were
then cultured in modified Eagle’s medium with 10 mM butane-
dione monoxime and 0.1% bovine serum albumin (BSA) at 5%
CO2 before any treatment.
Rat Neonatal Cardiac Myocyte Preparation—Primary cul-
tures of rat neonatal cardiac myocytes were prepared as
described previously with minor modifications (23). Myocytes
were dispersed fromventricles of 1- to 2-day-old Sprague-Daw-
ley rats using 0.04% collagenase II and 0.05% pancreatin at
37 °C. Non-cardiomyocytes were eliminated by pre-plating for
1.5 h at 37 °C. Myocytes were cultured in cell culture medium
containing Dulbecco’s modified Eagle’s medium andM199 (4:1
v/v) with 10% fetal bovine serum. The neonatal cardiac myo-
cytes were serum-starved for 48 h before experimentation. For
experiments containing 10% fetal bovine serum, cells were cul-
tured 48 h after plating with one time media change before
treatment.
Lactate Dehydrogenase Measurement, Annexin V Staining,
and TUNEL Assay for Cell Apoptosis—For lactate dehydrogen-
ase measurement, rat neonatal myocytes were treated with
MBG or the combination of MBG and rapamycin. The cul-
ture medium of treated cells was collected and centrifuged at
16,000  g for 5 min to remove dead cells. The supernatant
was transferred to a new tube for lactate dehydrogenase meas-
urement using a commercial kit from Roche Applied Science.
Rat neonatal myocytes grown on glass coverslips were used for
annexin V staining and TUNEL assay. The annexin V staining
kits was from Invitrogen. Themanufacturer’s instructions were
followed for annexin V staining with minor modifications.
Briefly, rat neonatal myocytes were stained with annexin V and
PI in annexin V assay buffer for 15 min. The cells were washed
twice with PBS and slightly fixed with 2% paraformaldehyde for
15 min. These cells were then examined using a Leica confocal
microscope (Buffalo Grove, IL) on the same day. TUNEL assay
was performedon rat neonatalmyocytes using a commercial kit
from Millipore (Billerica, MA) following the manufacturer’s
instructions. Treated cells were first fixed and permeabilized
with cold methanol. TUNEL-positive cells were stained with
streptavidin-FITC after terminal deoxynucleotidyl transferase
incubation and examined using a Leica confocalmicroscope. PI
is used for counterstaining the nuclei.
Statistics—Continuous data are presented as themean S.E.
Statistical analysis was performed using the Student’s t test, and
significance was accepted at p 0.05.
RESULTS
MBG Infusion Induces Myocyte Apoptosis, Cardiac Dysfunc-
tion, Ventricular Dilation, and Reduced Wall Thickness in
1/Mice—Decreased Na/K-ATPase and increased endoge-
nous CTS have been found in patients with congestive heart
failure and chronic kidney diseases (16–18). To test whether
Na/K-ATPase reduction potentiates CTS-induced cardiac dys-
function, Na/K-ATPase 1/ mice with one allele of the
Na/K-ATPase 1 gene deleted, and their wild type littermates
were used in the MBG infusion studies. Both WT and 1/
micewere infusedwithMBG through an osmoticmini pump at
a dose of 10 g/kg/day. This concentration of MBG has been
used in our previous studies without observable toxicity (24,
25). Mice infused with solvent only were used as control. Echo-
cardiograph measurement was performed at the end of 4th
week post implantation of themini pump. As shown in Table 1,
MBG infusion significantly increased the systolic and diastolic
dimension of the left ventricle in 1/ mice when compared
with the wild type controls. Consistently, the septal wall thick-
ness reduced over time afterMBG infusion in1/mice from
1.31 0.38mm at base line to 0.78 0.09mm at the end of 4th
week, whereas in theWTmice, there was no significant change
observed. Functionally, MBG infusion also caused 45%
reduction in contractile function of the left ventricle in 1/
mice but had less of an effect in WT mice.
Cardiac myocyte apoptosis has been found to cause
decreased wall thickness and increased chamber dilation (26,
27), whereas we have shown that reduction of Na/K-ATPase
potentiates cell death in cultured epithelial cells (15). To test
whether cardiac myocyte death plays a role in left ventricle
dilation and cardiac dysfunction in the Na/K-ATPase 1/
mice, we first examined the left ventricle slides stained with
hematoxylin and eosin (H&E) and found no significant tissue
damage or vacuoles in any of the experimental groups.We then
further examinedwhether cardiacmyocytes undergo apoptosis
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in these tissue slides. Although TUNEL assay is a commonly
used method for detection of cell apoptosis, it is a demonstra-
tion of a late event in the process of cell death and is detectable
only for a fewhours (28). Thus, we used immunohistochemistry
against active caspase 3 as an indicator of cells undergoing apo-
ptosis. As shown in Fig. 1A,WT and1/ controlmice as well
as MBG-infused WTmice exhibit very low positive staining of
active caspase 3 (1% of the total area) in heart tissue, but the
positive staining of active caspase 3 more than doubled in
MBG-infused 1/ mice, indicating that Na/K-ATPase
reduction potentiates MBG-induced cell apoptosis. Fig. 1B
demonstrates that expression of 1 Na/K-ATPase in cardiac
tissue homogenates from 1/ mice was 38% lower than
that observed in WT control mice, which is consistent with
previous observations (11). Infusion of MBG tended to further
decrease the expression of Na/K-ATPase 1 but in a manner
that was not statistically significant in heart tissues from 1/
mice (Fig. 1B).
Caspase 3 is one of the executive caspases that can be acti-
vated by caspase 8 through the death receptor-initiated apopto-
tic pathway or by caspase 9 of the mitochondria-involved
apoptotic pathway. To delineate the specific pathway in MBG-
inducedmyocyte apoptosis, we isolated adult cardiac myocytes
from both WT and 1/ mice as described under “Experi-
mental Procedures” and treated the cells with MBG for 24 h.
After the treatment period, cells were lysed in RIPA buffer, and
cell lysates were used to probe for the presence of caspase 8 and
caspase 9. The anti-caspase 8 and anti-caspase 9 antibodies rec-
ognize both the pro- and active forms of the respective
caspases. As shown in Fig. 2A, MBG treatment increased active
caspase 9 levels (the 35-kDa band resulted from the cleavage of
a 47-kDa procaspase 9) in cells isolated from 1/ mice but
not in cells from WT mice. However, no cleavage of caspase 8
was detected in any of the control or treated groups. To exam-
ine whether cardiac myocytes from hearts of 1/ mice are
more sensitive to MBG-induced cell death, we measured cell
survival rate of adult cardiac myocytes isolated from wild type
and 1/ mice after treatment with MBG. Live (rod-shaped)
and dead (round-shaped) cells were counted under a 20 light
microscope. As shown in Fig. 2B, MBG treatment for 24 h
resulted inmuchmore cell death in 1/myocytes compared
with that the level of cell death observed in WT myocytes.
Definitive assertions are difficult to assign to themorphological
results obtained in these studies. Although observing changes
FIGURE 1. MBG infusion induces caspase 3 activation in 1/ mice.
A, immunohistochemistry of active caspase 3 on left ventricle tissue from
control and MBG-infused WT and 1/ mice. The tissue slides were incu-
bated with anti-active caspase 3 antibody after performing antigen retrieval.
They were then incubated with a secondary antibody conjugated with HRP,
and the brown colorwas developedby adding its substrate 3,3-diaminoben-
zidine tetrahydrochloride (DAB). The upper panel is a representative image,
and the lower panel shows the quantitative data of positive staining using
ImageJ analysis. B, Na/K-ATPase 1 expression in left ventricle homogenates
fromcontrol orMBG-infusedWTand1/mice.GAPDHwasusedas loading
control. *, p 0.05 versusWT control. *, p 0.05, WT versus 1/ (n	 6 for
each group).
TABLE 1
Doppler image study in WT and Na/K-ATPase knockdown (1/) mice with MBG infusion
EDD, end diastolic dimension; ESD, end systolic dimension; BW, body weight; HW, heart weight; LVW, left ventricle weight; SWT, anterior wall thickness; PWT, posterior
wall thickness; shortening (%)	 (EDD ESD)/EDD 100). Data are presented as mean S.E. (*, p 0.05, base line versus 4 weeks).
Variables
WT 1/
Control MBG Control MBG
Base line 4 wk Base line 4 wk Base line 4 wk Base line 4 wk
HR (beat/min) 439 11 473 40 453 31 451 26 475 29 492 20 422 29 447 11
EDD (mm) 3.86 0.27 3.75 0.14 3.15 0.27 3.37 0.19 3.77 0.21 3.65 0.16 3.43 0.23 4.29 0.14*
ESD (mm) 2.25 0.18 2.12 0.19 1.61 0.25 2.10 0.14 2.27 0.15 2.23 0.10 1.81 0.26 3.12 0.13*
PWT (mm) 1.05 0.10 1.27 0.16 1.06 0.05 0.99 0.07 0.90 0.07 1.03 0.14 0.92 0.04 0.71 0.04*
SWT (mm) 1.07 0.01 0.94 0.05 1.42 0.14 1.32 0.10 1.03 0.07 0.92 0.04 1.31 0.38 0.78 0.09*
Shortening (%) 41.8 1.7 43.2 4.8 50.4 4.6 39.3 2.5 40.0 1.3 36.5 2.0 47.8 4.2 24.3 4.5*
HW/BW (mg/g) 3.9 0.2 4.0 0.2 3.8 0.1 4.1 0.1
LVW/BW (mg/g) 2.9 0.3 3.0 0.1 3.1 0.1 3.2 0.1
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in cell morphology (i.e. round up) in adult myocytes is a sensi-
tive indicator of cell damage, however, it is difficult to identify
the specific mechanism of cell death based only on cell count-
ing. When the results are combined with the data detailing
the activation of apoptotic pathway components, these
results become clearer and suggest that reduction of Na/K-
ATPase 1 may potentiate MBG-induced cardiac myocyte
apoptosis through activation of caspase 9, although it is hard
to exclude the involvement of necrosis or other cell death
mechanisms.
Na/K-ATPase ReductionAttenuates Survival Signaling Path-
ways in Cardiac Myocytes—It is reported that activation of the
AKT/mTOR signaling pathway protects cells from death by
regulating the phosphorylation of BAD (Bcl-2-associated death
promoter) and downstream caspase 9 activity (29). To further
understand how reduction of Na/K-ATPase potentiates MBG-
induced cardiac cell death, we analyzed the activation of the
AKT/mTOR pathway in cardiac myocytes isolated from both
1/ mice and their WT littermates. The isolated adult car-
diac myocytes were treated with different concentrations of
MBG for 15 min and then assayed for activation of the Src and
mTOR signaling pathways using Western blots. As shown in
Fig. 3, MBG induces phosphorylation of Src, AKT, and S6K in
cardiac myocytes from wild type mice. The activation of S6K
also results in an increased phosphorylation of BAD at Ser136,
which has been reported to block the activation of the caspase 9
pathway (29). However, in myocytes isolated from 1/mice,
MBG treatment cannot further phosphorylate S6K and BAD,
despite the slightly higher basal phosphorylation levels of these
proteins compared with the cells from WT mice, indicating
FIGURE 2.Na/K-ATPase reduction potentiatesMBG-induced activation of caspase 9 and cardiac cell death. A, cardiacmyocytes were isolated fromboth
WT and 1/mice andwere treatedwith different concentration of MBG for 24 h. The cell lysates were collected in RIPA buffer to probe for Na/K-ATPase 1,
caspase 9, and caspase 8 usingWestern blot. Tubulin was used for loading control (Con). The 35-kDa band of caspase 9 indicates the activation of procaspase
9 (a 47-kDa protein). B, isolated adult cardiac myocytes were treated with 1 M MBG for 24 h. Live cells (rod-shaped) and dead cells (round-shaped) were
countedunder amicroscope (20) for eachgroup. The left panel shows the representative imagesof adultmyocytesof control andMBG-treated cells. The right
panel is the quantification data from three different preparations. *, p 0.05, control versusMBG treatment.
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that Na/K-ATPase reduction causes deficiency of cell survival
signaling.
To examine the deficiency of the survival signaling pathways
in vivo, we carried out Western blots on left ventricle homoge-
nates to probe for BAD phosphorylation and activation of
caspase 9. As shown in Fig. 4A, MBG infusion in WT mice
induced phosphorylation of BAD at Ser136 but fails to do so in
the 1/mice.Meanwhile, MBG-infusion induces the activa-
tion of caspase 9 in heart tissue of 1/mice but not in that of
WT mice (Fig. 4B).
Inhibition ofmTORActivationMakes CardiacMyocytes Vul-
nerable to MBG Treatment—The above data indicate that the
deficiency of the Akt/mTOR signaling pathway in cardiacmyo-
cytes of 1/ mice may potentiate MBG-induced caspase 9
activation. To further assess the role of mTOR activation in
MBG-induced apoptosis of cardiac myocytes, wemeasured the
effect of an mTOR inhibitor, rapamycin, on MBG-induced cell
death. Neonatal myocytes were employed for this set of exper-
iments because a large number of adult myocytes in culture
were annexin V-positive even under control experimental con-
ditions after being cultured for long periods of time.
As depicted in Fig. 5A, rat neonatalmyocyteswere pretreated
with rapamycin for 1 h, and then both control and rapamycin-
pretreated cells were exposed to MBG for 72 h in serum-free
medium. Although MBG alone at 1 mol/liter did not induce
significant cell death, indicated by a lower activity of lactate
dehydrogenase in the culture medium, the combination of
MBG and rapamycin significantly increased lactate dehydro-
genase release (Fig. 5A). To test whether MBG induces cardiac
myocyte death via caspase 9-involved apoptosis, rat neonatal
cardiac myocytes were treated withMBG alone or in combina-
tion with rapamycin for 72 h with or without 10% fatal bovine
serum, and cell lysates were collected in RIPA buffer to probe
for caspase 9 activation usingWestern blot. As shown in Fig. 5B,
pretreatment with rapamycin potentiated MBG-induced
caspase 9 activation. We also cultured neonatal myocytes on
coverslips and treated themwithMBG alone for 72h or in com-
bination with 10 nM rapamycin as described above. The cells
were then subject to annexin V staining or TUNEL assay to
detect apoptosis. For the annexin V assays, staining of phos-
phatidylserinewith green fluorescence indicates the integrity of
the cell membrane has been compromised, a feature found in
FIGURE 3. Na/K-ATPase reduction attenuates MBG-induced survival signaling in cardiac myocytes. Adult cardiac myocytes were isolated fromWT and
1/mice and treated with different concentrations of MBG for 15 min. The phosphorylation of Src (p-Src), AKT (p-AKT), p70s6K (p-S6K), and BAD (p-BAD)
were probed using Western blot. Tubulin was used as loading control. The upper panel shows the representative Western blots. The lower panel shows the
quantification data for p-Src, p-Akt, p-S6K and p-BAD from three different experiments. *, p 0.05, control (Con) versusMBG treatment.
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16394 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 20•MAY 11, 2012
apoptosis. The red fluorescence of PI indicates the necrotic or
late apoptotic cells. As shown in Fig. 6A, rapamycin treatment
potentiated MBG-induced apoptosis but did not induce signif-
icant necrosis. Through the use of TUNEL assays, we further
confirmed that mTOR pathway inhibition by rapamycin
increased the ratio of apoptotic cells as indicated by the green
fluorescence staining in the cell nuclei (Fig. 6B). PI was used for
counterstaining to calculate the TUNEL-positive cell ratio in
the TUNEL assay.
DISCUSSION
CTS compounds such as digoxin have been used in clinical
treatment of heart failure despite the fact that their toxicity is
well documented. The Digitalis Investigation Group Trial (30)
found that there was a strong correlation between high serum
digoxin concentration and increased mortality in congestive
heart failure patients. Our current study suggests that the effect
of CTS may also depend on changes in the amount of heart
tissue Na/K-ATPase, the membrane receptor for CTS. Reduc-
tion of Na/K-ATPase in heart tissue potentiates MBG-induced
myocyte apoptosis and cardiac dysfunction. Clinically, these
potential pathological effects are highly relevant to the thera-
peutic use of digoxin. Decreases of Na/K-ATPase, which
accompany some disease states, may reduce the tolerance of
digoxin treatment. The combination of increased CTS levels
and decreased Na/K-ATPase content may contribute to the
worsened cardiac function observed with these diseases.
Previous studies have documented that CTS can regulate cell
growth and cell survival in different cell types (12). Our previ-
ous publication (15) and the current study have demonstrated
that Na/K-ATPase content is an important regulator of CTS-
induced toxicity. Reducing Na/K-ATPase content by itself may
not immediately cause cell death, but it potentiates MBG-in-
duced myocyte apoptosis by activation of the caspase 9-regu-
lated proapoptotic pathway. Unfortunately, it is not clear what
upstream factors causes activation of caspase 9 in this process.
However, one possibility is that long term exposure to MBG
may cause an accumulation of ion concentration such as that
expected with calcium overload, which can induce the activa-
tion of apoptotic pathways (31, 32). However, this may not fully
explain the differences in cell apoptosis levels observed inmyo-
cytes from WT and Na/K-ATPase 1/ mice because our
previous studies have shown that reduction of Na/K-ATPase
content by 60% results in onlyminimal differences in the 86Rb
uptake in proximal tubule cells, i.e. Na/K-ATPase ion homeo-
static activity (33). On the other hand, our results demonstrate
FIGURE 4.Na/K-ATPase reduction causes MBG-induced caspase activation and attenuates MBG-induced BAD phosphorylation. A, left ventricles from
WT and 1/mice were homogenized and probed for BAD phosphorylation at Ser136 usingWestern blot. B, left ventricle homogenates fromWT and 1/
mice were probed for procaspase 9 and active caspase 9. *, p 0.05, MBG treatment versus control (Con).
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that CTS compounds stimulate the Src/Akt/mTOR pathway,
which is known to down-regulate caspase 9 activation and in
doing so prevent cell death. We have shown in previous publi-
cations (33, 34) that reducing Na/K-ATPase using siRNA or
blocking the signaling function of Na/K-ATPase in renal prox-
imal tubule cells potentiates CTS-induced cell death. The cur-
rent study further supports these findings suggesting that
reduction of Na/K-ATPase affects MBG-induced further acti-
vation of this survival signaling pathway in cardiac myocytes.
Thus, we reasoned that CTS compounds may have a potential
to induce cell death pathways, but in normal cells, the death
pathway is balanced by the activation of a survival signaling
pathway and are therefore more resistant to CTS-induced cell
death. OnceNa/K-ATPase is reduced, the cell survival and pro-
apoptotic events will become unbalanced and subsequently
results in caspase 9 activation and cell apoptosis. The usage of
rapamycin further demonstrated that inhibition of mTOR sur-
vival signaling pathway is sufficient to potentiate the MBG-
induced cardiac myocyte apoptosis.
Despite the finding that signaling events stimulated by CTS
play a role in protecting normal cells from apoptosis, we also
noticed that reduction of Na/K-ATPase increases the basal
level of Src, Akt, and BAD phosphorylation in themyocytes but
has no protective effect on cell death or on caspase 9 activation
when treated withMBG (Figs. 3 and 4). In in vitro studies, CTS
compounds usually induce a transient activation of Src and its
FIGURE 5.Blocking of themTORpathwayby rapamycin potentiatesMBG-induced caspase 9 activation in rat neonatal cardiacmyocytes. Rat neonatal
myocytes were serum-starved for 48 h and treated with different concentrations of MBG or MBG combined with 10 nM rapamycin for 72 h. A, lactate
dehydrogenase (LDH) measurement using the culture media from control or MBG-treated cells. B, rat neonatal myocytes were treated with MBG alone or in
combinationwith rapamycin in serum-freeor 10% fatal bovine serummedia. Cell lysateswere collected in RIPAbuffer for probingof caspase 9. Theupper panel
shows the representative Western blot of procaspase 9 and active caspase 9. The lower panel shows the quantitative data of active caspase 9 from three
different preparations of neonatal cardiac myocytes. *, p 0.05, MBG-treated cells in the presence of 10 nmol/liter rapamycin versus those in the absence of
rapamycin.
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downstream signaling components at a time peak of 15–30min
(34, 35), but long term effects in in vivo experiments have not
been well studied. Our results indicate that the transient
response to MBG treatment seems to be correlated with myo-
cyte survival while the constant increased phosphorylation of
these kinases did not protect cells fromMBG-induced cell apo-
ptosis. Interestingly, transient activation of ERK promotes cell
growth, whereas constant activation of ERK induces cell death
(36). However, it is not clear whether a similar mechanismmay
apply to the kinases studied in our experimental conditions.We
also acknowledge that our experiments did not exclude the
involvement of other cell deathmechanisms such as necrosis or
oncosis after MBG treatment. A major problem in identifying
thesemechanisms is the lack of specific markers for these path-
ways, and levels of activation are often judged bymorphological
changes of the cells (37). Because most of our in vitro experi-
ments were conducted in serum-freemedium to avoid the con-
founding effect of other growth factors in serum, they may not
fully represent the physiological conditions.However, as shown
in Fig. 5B, MBG induces activation of caspase 9 at both serum-
free and serum-containing conditions in the presence of rapa-
mycin. Taken together with our in vivo study, we believe that
the studies presented here support the relationship between
Na/K-ATPase reduction, signaling activation, and cardiac
myocyte apoptosis.
The current study also indicates thatMBG-inducedmyocyte
apoptosis may contribute to reduced left ventricle wall thick-
ness and chamber dilation in1/mice. Apoptosis may cause
myocyte number to decrease, induce side to side slippage, as
well as increase lengthening of myocytes within the ventricle
wall, resulting in increased ventricle volume (20, 27). However,
the decreased wall thickness did not seem to decrease the heart
organ weight or its ratio to bodyweight in these mice (Table 1).
It is not clear whether the lengthening of individual myocytes
compensates for the overall mass loss or if the observed
increase in myocyte death is not sufficient to elicit a significant
organ weight loss in the time period of our experiment. Further
studies are merited to elucidate the phenomena.
In summary, our experimental results suggest that Na/K-
ATPase and its specific ligands are involved in the etiology of
cardiac dysfunction. The reduction of Na/K-ATPase may serve
as a novel mechanism that potentiates CTS-induced cardiac
cell apoptosis and dilated cardiomyopathy.
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